Meet Our 2024 Diversity Fellow Lisa Qian

Seeger Weiss is proud to introduce our 2024 Diversity Fellow, Lisa Qian. This summer, Lisa is assisting in drafting pre-trial motions for the GLP-1 MDL, in addition to helping with the preparations for various upcoming hearings. We are thrilled to be a part of Lisa’s journey into plaintiff’s litigation. Having recently completed her first year […]

July 1, 2024

Seeger Weiss is proud to introduce our 2024 Diversity Fellow, Lisa Qian. This summer, Lisa is assisting in drafting pre-trial motions for the GLP-1 MDL, in addition to helping with the preparations for various upcoming hearings. We are thrilled to be a part of Lisa’s journey into plaintiff’s litigation.

Having recently completed her first year at Stanford Law, Lisa is on track to graduate with her Juris Doctor in June 2026. She is heavily involved in the Stanford community, serving as a member editor of the Stanford Law Review, co-president of the Plaintiff’s Law Association, co-leader of the Title IX Pro Bono Project, and a research assistant. Lisa graduated summa cum laude and Phi Beta Kappa from Yale University in May 2020 with a Bachelor of Arts in Economics and additional studies in human rights.

Prior to joining Seeger Weiss this summer, Lisa worked in the mass tort and litigation funding spaces. After realizing her passion for advocating on behalf of individuals wronged by powerful institutions, she knew plaintiff’s litigation was her calling. Lisa is especially drawn to sexual assault cases, where she can assist survivors in finding justice.

When she is not studying the law, Lisa enjoys spending her time writing fiction, one of her favorite pastimes. “Every lawyer secretly wants to be a novelist, too,” says Lisa.

Lisa was interested in Seeger Weiss after admiring the firm’s work in the Opioid, 3M Earplugs, and Social Media MDLs. She enjoys learning about the creative methods attorneys use in litigation, including partner Christopher Ayers, who has built a reputation for dynamic approaches and a fresh perspective to litigations. His work on the Henrietta Lacks case is of particular inspiration.

Seeger Weiss believes a diverse legal team is more effective and better positioned to serve clients’ needs. In line with this commitment, Seeger Weiss established the Seeger Weiss Diversity Fellowship, a program designed to support rising second-year law students who show exceptional promise and contribute meaningfully to the diversity of the legal community. Partner Parvin Aminolroaya is a key organizer of the Diversity Fellowship, and Lisa credits her as being a role model for women of color in Plaintiffs’ leadership.

Related News

March 30, 2026
Ten Seeger Weiss Attorneys Named To The 2026 Lawdragon 500 Leading Plaintiff Financial Lawyers Guide

Seeger Weiss is proud to announce that ten Seeger Weiss attorneys have been selected for inclusion in The 2026 Lawdragon 500 Leading Plaintiff Financial Lawyers guide. Congratulations to Christopher Seeger, Stephen Weiss, Parvin K. Aminolroaya, Ben Barnett, David R. Buchanan, Steven Daroci, Shauna Itri, Jeremy Kasha, Jennifer Scullion, and Caleb Seeley on this well-deserved recognition. […]

Read More
March 26, 2026
Jury Finds Meta and YouTube Liable in Landmark California Social Media Addiction Trial

A California jury has found Meta and YouTube negligent in designing platforms that harmed a young user, ordering Meta to pay $4.2 million and YouTube to pay $1.8 million in combined compensatory and punitive damages, in what is being called a landmark verdict in social media addiction litigation. Seeger Weiss Founding Partner Christopher Seeger serves […]

Read More
March 12, 2026
Seeger Weiss Partner Parvin Aminolroaya and Counsel Max Kelly Appointed to Leadership Roles in GLP-1 NAION Products Liability Litigation

Seeger Weiss is proud to announce that Partner Parvin Aminolroaya has been appointed Co-Lead Counsel for Plaintiffs in the In Re: GLP-1 RAS Non-arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation and Counsel Max Kelly has been appointed to the Plaintiffs’ Executive Committee. The litigation involves claims that GLP-1 receptor agonist drugs including Ozempic, Wegovy, […]

Read More